Table 2.
Prevalence and persistence in use of psychotropic drugs
| Prevalence n (%) | ||||||
|---|---|---|---|---|---|---|
| A1 | A2 | A3 | ||||
| All | D/nD | All | D/nD | All | D/nD | |
| (N = 1001) | (N = 415/586) | (N = 599) | (N = 304/295) | (N = 453) | (N = 227/226) | |
| Psychotropic drug use | ||||||
| Antipsychotics (AP) | 36 (3.6) | 24/12 (5.8/2.0)** | 28 (4.7) | 22/6 (7.2/2.0)** | 30 (6.6) | 26/4 (11.5/1.8)*** |
| Traditional AP | 31 (3.1) | 19/12 (4.6/2.0)* | 23 (3.8) | 17/6 (5.6/2.0)* | 23 (5.1) | 19/4 (8.4/1.8)** |
| Atypical AP | 5 (0.5) | 5/0 (1.2/0) | 6 (1.0) | 6/0 (2.0/0) | 8 (1.8) | 8/0 (3.5/0) |
| Antidepressants | 155 (15.5) | 82/73 (19.8/12.5)** | 121 (20.2) | 80/41 (26.3/13.9)*** | 101 (22.3) | 70/31 (30.8/13.7)*** |
| Anxiolytics | 86 (8.6) | 43/43 (10.4/7.3) | 71 (11.9) | 48/23 (15.8/7.8)** | 53 (11.7) | 35/18 (15.4/8.0)* |
| Sedatives | 221 (22.1) | 103/118 (24.8/20.1) | 128 (21.4) | 78/50 (25.7/16.9)* | 103 (22.7) | 59/44 (26.0/19.5) |
| Anti-dementia drugs | 57 (5.7) | 53/4 (12.8/0.7)*** | 60 (10.0) | 57/3 (18.8/1.0)*** | 34 (7.5) | 31/3 (13.7/1.3)*** |
| Any PTD | 403 (40.3) | 208/195 (50.1/33.3)*** | 272 (45.4) | 178/94 (58.6/31.9)*** | 210 (46.4) | 132/78 (58.1/34.5)*** |
| Persistence n (%) | ||||||
| A1-A2 | A2-A3 | |||||
| All | D/nD | All | D/nD | |||
| Psychotropic drug use | ||||||
| Antipsychotics (AP) | 17 (63.0)a | 12/5 (63.2/62.5) | 13 (65.0)a | 10/3 (62.5/75.0) | ||
| Traditional AP | 13 (54.2) | 8/5 (50.0/62.5) | 11 (64.7) | 8/3 (61.5/75.0) | ||
| Atypical AP | 3 (100) | 3/0 (100/0) | 1 (25.0) | 1/0 (25.0/0) | ||
| Antidepressants | 83 (82.2) | 45/38 (83.3/80.9) | 69 (82.1) | 41/28 (80.4/84.8) | ||
| Anxiolytics | 29 (63.0) | 17/12 (70.8/54.5) | 22 (57.9) | 14/8 (53.8/66.7) | ||
| Sedatives | 77 (66.4) | 37/40 (68.5/64.5) | 52 (67.5) | 27/25 (71.1/64.1) | ||
| Anti-dementia drugs | 26 (74.3) | 24/2 (75.0/66.7) | 22 (66.7) | 20/2 (64.5/100) | ||
| Any PTD | 191 (81.3) | 106/85 (86.9/75.2)* | 142 (83.5) | 85/57 (85.9/80.3) | ||
A1: Assessment 1, at baseline
A2: Assessment 2, 18 months after baseline
A3: Assessment 3, 36 months after baseline
D Dementia, nD No dementia, PTD Psychotropic drugs
* p < 0.05; ** p < 0.01; *** p < 0.001; p-values were calculated by generalized linear mixed model adjusting for municipality level if present
aOne participant changed between traditional AP and atypical AP between assessments, which is why the numbers of persistent users of traditional AP plus persistent users of atypical AP does not equal persistent users of antipsychotics. This is the case for A1-A2 and A2-A3